Biomet Roars Back
Five years ago, Biomet was in turmoil, as the board announced the company was for sale and the company's long-time CEO stepped down. The eventual buyers: a group of leading private equity firms. Biomet still faced a number of internal challenges, including fixing a spine and trauma business that was performing poorly. Critical to Biomet's turnaround was re-establishing the culture of stability that had long characterized the company. At the same time, it now has a new, more aggressive focus on capturing market share commensurate with its role as a top orthopedics company.
You may also be interested in...
One of the most innovative and creative orthopedic implant designers, the UK's Finsbury's Orthopedics never quite built the sales and distribution capability to enable it to capture the full value of its designs. The company's recent sale to DePuy underscores how much the orthopedics industry has changed since its earliest days.
Since becoming CEO of orthopedics giant Zimmer two years ago, David Dvorak has faced a host of challenges unprecedented in this booming market, including a federal investigation into and settlement of questionable relationships with customers and the most severe economic crisis in 30 years. But Dvorak seems calm and confident as he looks ahead.
Though government officials and critics in the press painted lucrative consulting arrangements as unscrupulous tools in the hands of Big Ortho, no one's happier to see them go than the orthopedics industry itself. Here’s how the details shake out for the industry, and why executives are actually relieved to have some sticky legal and moral issues disappear. Some even predict that the end result will be lower overhead for their companies.